Los Angeles, CA – March 6, 2026 – Dr. Dimitrios Iliopoulos, CEO and co-founder of AthosOmics.AI (part of Athos Therapeutics Inc.), will participate as a featured speaker in a high-profile panel discussion at The Montgomery Summit, taking place March 10-11, 2026, at the Fairmont Miramar Hotel & Bungalows in Santa Monica.
The session, titled “AI-Driven Drug Discovery & Clinical Development,” is scheduled for 9:30 AM – 10:15 AM on March 10th and will be moderated by Amgen. It brings together leaders from pioneering AI-enabled biotechnology companies currently advancing candidates into human trials, including Athos Therapeutics (in Phase II).
The panel will explore how artificial intelligence is transforming the drug discovery landscape – dramatically compressing timelines from concept to clinical-stage development, reimagining molecule design, stratifying patient subpopulations, and fostering new models of collaboration between agile startups and global pharmaceutical leaders. Attendees will gain insights into real-world successes already delivering results, as well as forward-looking perspectives on the next decade of AI-powered innovation in therapeutics.
Dr. Iliopoulos, a renowned expert in artificial intelligence, systems biomedicine, and precision therapeutics, brings deep experience to the conversation. His academic background includes roles as Assistant Professor at Harvard Medical School and tenured Associate Professor at UCLA School of Medicine, where he founded the UCLA Center for Systems Biomedicine. Recognized on Stanford’s list of the top 2% of scientists worldwide, he has received prestigious awards from the NIH, Sidney Kimmel Foundation, and Leona & Harry Helmsley Foundation for groundbreaking work in identifying novel targets and developing treatments for autoimmune diseases and cancer.
At AthosOmics.AI, Dr. Iliopoulos leads an innovative AI software platform that integrates multi-omics data (genomics, transcriptomics, proteomics, and more) from over 30,000 patient samples with longitudinal patient clinical datasets to identify novel drug targets, design small molecules, stratify patients, and accelerate precision medicine. The platform offers no-code, automated solutions, that power Athos Therapeutics’ pipeline, including ATH-063, a first-in-class AI-generated G9A methyltransferase inhibitor now in Phase II clinical trials for inflammatory bowel disease. AthosOmics.AI enables rapid, secure analysis of raw omics data to uncover biomarkers, therapeutic targets, and molecular pathways, with applications extending beyond drug discovery into other omics-driven industries.
The Montgomery Summit, presented by March Capital, is one of the nation’s premier invitation-only technology conferences, convening over 1,200 accomplished entrepreneurs, investors, and executives to explore the most impactful innovations in business and technology through world-class programming, networking, and insights.
“We are honored to have Dr. Iliopoulos represent AthosOmics.AI on this prestigious panel,” said Allan J. Pantuck, MD, MS, Chairman and Chief Medical Officer of Athos. “His participation underscores the growing momentum of AI in delivering tangible breakthroughs in drug development and positions AthosOmics.AI at the forefront of reshaping how precision therapeutics reach patients faster and more effectively.”
For more information about The Montgomery Summit, visit https://montgomerysummit.com/
To learn more about AthosOmics.AI and Athos Therapeutics, visit https://athosomics.ai/ or https://athostx.com/
About AthosOmics.AI and Athos Therapeutics Inc.
AthosOmics.AI is the AI software division of Athos Therapeutics Inc., a clinical-stage biotechnology company pioneering precision small molecule therapeutics for immune-mediated and autoimmune diseases. Leveraging advanced computational algorithms, multi-omics integration, and patient-derived data, AthosOmics.AI accelerates target identification, drug design, and development – enabling faster, more precise therapies while offering no-code omics analysis solutions across industries.
Contact:
Keith Hoffman, PhD, CBO of AthosOmics.AI and Athos Therapeutics Inc.
khoffman@athostx.com